Affinity DataKi: 7.30E+6nMAssay Description:Inhibition of Trypanosoma cruzi trans-SialidaseMore data for this Ligand-Target Pair
Affinity DataKi: 1.23E+7nMAssay Description:Inhibition of Trypanosoma cruzi trans-SialidaseMore data for this Ligand-Target Pair
TargetGlycylpeptide N-tetradecanoyltransferase 1(Homo sapiens (Human))
Frontier Medicines
Curated by ChEMBL
Frontier Medicines
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human N-myristoyltransferase assessed as reduction in CoASH production by fluorogenic detection based assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of beta2 adrenoreceptor (unknown origin)More data for this Ligand-Target Pair
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Frontier Medicines
Curated by ChEMBL
Frontier Medicines
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human PDE10A2 using cAMP substrate by HTRF assayMore data for this Ligand-Target Pair
In DepthDetails
TargetCyclin-dependent kinase 4(Oryctolagus cuniculus (Rabbit))
Astex Therapeutics Ltd.; Novartis AG
US Patent
Astex Therapeutics Ltd.; Novartis AG
US Patent
Affinity DataIC50: 3nMpH: 7.5Assay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In DepthDetails
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.30nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
In DepthDetails
In DepthDetails
In DepthDetails
TargetCyclin-dependent kinase 4(Oryctolagus cuniculus (Rabbit))
Astex Therapeutics Ltd.; Novartis AG
US Patent
Astex Therapeutics Ltd.; Novartis AG
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4(Oryctolagus cuniculus (Rabbit))
Astex Therapeutics Ltd.; Novartis AG
US Patent
Astex Therapeutics Ltd.; Novartis AG
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In DepthDetails
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 4.5nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
In DepthDetails
In DepthDetails
In DepthDetails
In DepthDetails
In DepthDetails
In DepthDetails
In DepthDetails
TargetCyclin-dependent kinase 4(Oryctolagus cuniculus (Rabbit))
Astex Therapeutics Ltd.; Novartis AG
US Patent
Astex Therapeutics Ltd.; Novartis AG
US Patent
Affinity DataIC50: 5nMpH: 7.5Assay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
In DepthDetails
In DepthDetails
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5.80nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of human HPGDS assessed as reduction in PGD2 formation using PGH2 as substrate by mass spectrometryMore data for this Ligand-Target Pair
TargetEpithelial discoidin domain-containing receptor 1(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of DDR1 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6.10nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
In DepthDetails
In DepthDetails
In DepthDetails
In DepthDetails
Affinity DataIC50: 8nMAssay Description:Inhibition of human HPGDS assessed as reduction in PGD2 formation using PGH2 as substrate by mass spectrometryMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4(Oryctolagus cuniculus (Rabbit))
Astex Therapeutics Ltd.; Novartis AG
US Patent
Astex Therapeutics Ltd.; Novartis AG
US Patent
Affinity DataIC50: 8nMpH: 7.5Assay Description:A 384-well microtiter Lance TR-FRET (time-resolved-fluorescence energy transfer) endpoint assay was used for CDK4/cyclin D1 kinase activity measureme...More data for this Ligand-Target Pair
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8.10nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
Affinity DataIC50: 8.20nMAssay Description:Inhibition of full-length human His6-tagged HPGDS expressed in Escherichia coli BL21 (DE3) using PGH2 as substrate measured after 90 to 120 secs by R...More data for this Ligand-Target Pair
TargetDiscoidin domain-containing receptor 2(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8.20nMAssay Description:Inhibition of DDR2 (unknown origin) after 1 hr by time resolved fluorescence methodMore data for this Ligand-Target Pair
In DepthDetails
Affinity DataIC50: 9nMAssay Description:Inhibition of human HPGDS assessed as reduction in PGD2 formation using PGH2 as substrate by mass spectrometryMore data for this Ligand-Target Pair
Affinity DataIC50: 9.70nMAssay Description:Inhibition of full-length human His6-tagged HPGDS expressed in Escherichia coli BL21 (DE3) using PGH2 as substrate measured after 90 to 120 secs by R...More data for this Ligand-Target Pair
TargetMast/stem cell growth factor receptor Kit(Homo sapiens (Human))
Astex Pharmaceuticals
Curated by ChEMBL
Astex Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9.80nMAssay Description:Inhibition of c-Kit (unknown origin) using biotinylated HER2 peptide as substrate by time resolved fluorescence methodMore data for this Ligand-Target Pair
Affinity DataIC50: 9.90nMAssay Description:Inhibition of full-length human His6-tagged HPGDS expressed in Escherichia coli BL21 (DE3) using PGH2 as substrate measured after 90 to 120 secs by R...More data for this Ligand-Target Pair
In DepthDetails
Affinity DataIC50: 10nMAssay Description:Inhibition of human HPGDS assessed as reduction in PGD2 formation using PGH2 as substrate by mass spectrometryMore data for this Ligand-Target Pair